Summary & Overview
HCPCS J9207: Ixabepilone Injection, 1 mg
HCPCS Level II code J9207 designates a 1 mg unit of ixabepilone administered by injection, a chemotherapy agent used in oncology care. Nationally, accurate coding for chemotherapeutic agents matters for clinical documentation, hospital and outpatient infusion billing, and consistent reimbursement across payers. Ixabepilone is typically used in specialized cancer care settings and billed per milligram using HCPCS Level II codes.
Key payers included in this analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of what the code represents, typical sites of service, and which major payers are relevant for coverage and claims processing. The publication provides benchmarking context, common billing considerations, and clarifies where policy updates may affect coverage and payment for oncology drug administration.
This summary equips billing managers, clinical coders, and revenue cycle stakeholders with the essential context needed to handle claims that include J9207, including expected use in outpatient infusion centers and hospital outpatient departments. Data not available in the input is noted where relevant in detailed sections.
Billing Code Overview
HCPCS Level II code J9207 represents an injection of ixabepilone, 1 mg. This code denotes the administration of the chemotherapeutic agent ixabepilone in discrete 1 mg units for oncology treatment.
-
Service type: Intravenous chemotherapeutic drug administration
-
Typical site of service: Outpatient oncology infusion center or hospital outpatient department
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with metastatic or locally advanced breast cancer who has progressed on prior chemotherapy and is scheduled to receive intravenous ixabepilone. The patient presents to an outpatient oncology infusion center or hospital outpatient infusion unit for administration. Pre-infusion nursing assessment documents vital signs, performance status, laboratory values (including complete blood count and liver function tests), and review of prior hypersensitivity or neuropathy. The oncology pharmacist prepares ixabepilone in an appropriate concentration, labels the syringe or infusion bag in milligrams, and verifies dose per body-surface area or weight-based order. The medication is administered via intravenous infusion or bolus per protocol, with monitoring for infusion reactions and neuropathic adverse effects. Post-infusion observation includes assessment for acute toxicity, recording the administered milligrams on the medication administration record, and billing one unit of J9207 per milligram of ixabepilone used when applicable. Documentation includes indication, consent, drug lot and NDC if required, exact dose administered, route, site, and any modifiers that reflect special circumstances of the service.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | Unspecified | Rarely used; not typically reported for outpatient drug administration unless payer-specific requirement mandates an unspecified modifier. |